⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669437 | 0.97 | — | — | |
| SCHEMBL712440 | 0.94 | — | — | |
| SCHEMBL710332 | 0.88 | — | — | |
| SCHEMBL3275613 | 0.72 | — | — | |
| SCHEMBL7709341 | 0.71 | KDM4E (0.31) | — | |
| SCHEMBL6668394 | 0.70 | — | — | |
| SCHEMBL10009873 | 0.70 | — | — | |
| SCHEMBL15210617 | 0.69 | — | — | |
| SCHEMBL17104753 | 0.67 | — | — | |
| SCHEMBL7094869 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171467-A1 | REDOX SUBSTRATES FOR LEUKOCYTE ESTERASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-10 | — | — | US | claimed |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | claimed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | claimed |
| EP-2051712-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2009-04-29 | — | — | EP | claimed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | claimed |
| WO-2008021375-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3571205-B1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| US-20210171467-A1 | REDOX SUBSTRATES FOR LEUKOCYTE ESTERASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-10 | — | — | US | disclosed |
| US-10759812-B2 | Thienopyrimidine derivative and use thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| EP-2852572-B1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190352311-A1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1262196-A2 | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1260221-A2 | Combination treatment for depression and anxiety | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1256578-A1 | Thiazole derivatives and their use as cdk inhibitors | Pfizer Products Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020103185-A1 | Pyrazole derivatives | PFIZER PRODUCTS INC. | 2002-08-01 | — | — | US | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |